Friday, 16 October 2026European Markets

BENEVOLENTAI Stock Bearish By 15% In The Last 5 Sessions

Loading stream...

UK-based biotech company, BenevolentAI has seen its stock shares plunge dramatically in the last week. With its shares currently valued at EUR1.13, the downfall in price marked a significant event in the trading market, drawing attention to the company's performance.

BenevolentAI's Stock Market Performance

In a span of just five sessions, BenevolentAI's shares dropped from EUR1.33 to EUR1.13. This represents a fall of 15.04%, extending from a previous losing streak across three sessions. The pattern observed matched the general trend of the AEX-Index index, which also saw a decline of 0.66%, dropping to EUR767.00.

A Year-Long Overview

The recent closing value for BenevolentAI stood at EUR1.12, exhibiting a massive decrease of 84.34% from its 52-week high of EUR7.15. An examination of the past year reveals that the company's earnings have been less than stellar. The Earnings per Share (EPS) figure fell into the negative with a value of EUR-1.74. Additionally, the return on equity (an industry-standard measure of profitability correlated with shareholder's equity), also dipped into the negative, registering at -152.53%.

Current Overview and Future Outlook

Although BenevolentAI's shares are well above its 52-week low of EUR1.10, they remain significantly below their peak value. In recent times, the shares have shown somewhat steady levels of volatility, averaging a negative swing of 6.93%, complemented by a negative monthly change of -1.19%. Signs of recovery have occasionally appeared for this biotech player, particularly when considering its quarterly performance.

Trading Volumes and Oscillator Patterns

Trade volumes for BenevolentAI have experienced a steep drop with the last reported volume indicating a decline of 89.75% from their regular numbers. The stochastic oscillator for the company presents it as potentially overbought, signalling the possibility of a future downturn for its stock.

More news about BENEVOLENTAI (BAI.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com